BlossomHill Therapeutics Welcomes Dr. Geoff Oxnard
BlossomHill Therapeutics, a promising clinical-stage biotechnology company, has taken an exciting step in strengthening its leadership team. The company has appointed Dr. Geoff Oxnard as its new Chief Medical Officer and Executive Vice President. This key appointment reflects BlossomHill's dedication to advancing innovative therapies for cancer and autoimmune diseases.
About Dr. Geoff Oxnard
Dr. Oxnard is renowned in the field of clinical and translational cancer research. Having spent nearly a decade at the prestigious Dana-Farber Cancer Institute and Harvard Medical School, he has made significant contributions to understanding the intricacies of cancer treatment. His research played a pivotal role in advancing clinical insights concerning the sensitivity and resistance of advanced lung cancer to EGFR inhibitors. Notably, he was instrumental in the identification of the EGFR C797S resistance mutation, which has had major implications for treatment strategies.
Vision and Goals
“Since our founding, we at BlossomHill Therapeutics have cultivated a strong pipeline of drug candidates,” said Dr. Jean Cui, the company’s President and CEO. “Welcoming Dr. Oxnard to our team enhances our capabilities. His extensive experience in precision medicine is invaluable as we progress through critical stages of our clinical development.”
Dr. Oxnard expressed his enthusiasm about joining BlossomHill during this crucial time. “I am truly excited to be a part of this dedicated team as we embark on our first two oncology programs through their first-in-human studies,” he remarked. He commended Dr. Cui for her drug design proficiency, which has already led to three FDA-approved therapies.
Dr. Oxnard's Extensive Background
Dr. Oxnard’s career has been distinguished by his commitment to bridging academic research with industry application, focusing on delivering precision oncology therapies. His vast experience encompasses over 200 scientific publications, showcasing his work across all aspects of cancer research, from genomic discoveries to pivotal clinical trials. Before joining BlossomHill, he was the Vice President and Global Head of Thoracic Cancers at Eli Lilly, where he advanced a diverse portfolio of thoracic treatments. His tenure at Foundation Medicine also highlights his role in supporting the approval of FoundationOne®Liquid CDx, crucial for monitoring cancer treatment responses.
Expanding Leadership Team
Alongside Dr. Oxnard’s appointment, BlossomHill Therapeutics has also welcomed Dr. Ashley Preston as Senior Vice President and Head of Regulatory Affairs and Quality Assurance. Dr. Preston brings a wealth of knowledge and experience in regulatory affairs, having previously served at Syros Pharmaceuticals. Her expertise is expected to further strengthen BlossomHill’s regulatory strategies, helping to navigate the complex landscape of developing innovative therapies.
About BlossomHill Therapeutics
BlossomHill Therapeutics specializes in the design and development of small molecule drugs targeting unmet medical needs, particularly in oncology and autoimmune diseases. The company is dedicated to advancing drug candidates across a variety of targets, aiming for significant progress in patient care. The team approaches drug design rooted in a profound understanding of disease mechanisms, which guides the creation of novel chemotypes to enhance treatment success. Based in San Diego, BlossomHill Therapeutics is backed by prominent investors, reinforcing its commitment to innovative and patient-centric solutions.
Frequently Asked Questions
Who has been appointed as Chief Medical Officer at BlossomHill?
Dr. Geoff Oxnard has been appointed as Chief Medical Officer and Executive Vice President at BlossomHill Therapeutics.
What is BlossomHill Therapeutics focused on?
BlossomHill Therapeutics focuses on the design and development of small molecule medicines, particularly for cancer and autoimmune diseases.
What notable contributions has Dr. Oxnard made to cancer research?
Dr. Oxnard is known for his work on EGFR inhibitors and the identification of the EGFR C797S resistance mutation in advanced lung cancer.
Who else joined the leadership team recently?
Dr. Ashley Preston has been appointed as the Senior Vice President and Head of Regulatory Affairs and Quality Assurance.
What is the mission of BlossomHill Therapeutics?
The mission of BlossomHill is to innovate and develop treatments that address unmet medical needs in oncology and autoimmune diseases.
